LY03017 vs Remlifanserin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Serotonin 5-HT2A receptor (antagonist / inverse agonist) · full Alzheimer's Disease pipeline
LY03017
Developed by Luye Pharma Group
NCT06388551 · Phase 1 · status unknown
This early-phase study randomly assigned healthy volunteers to ascending single oral doses of LY03017 or matching placebo under quadruple-blind conditions, tracking adverse events as the primary outcome. No results have been posted, so it remains a well-designed, blinded, placebo-controlled trial whose findings are not yet known. Its registered primary outcome on ClinicalTrials.gov is "Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
Remlifanserin
Developed by Acadia Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2028 · NCT06159673 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Alzheimer's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | LY03017 | Remlifanserin |
|---|---|---|
| CDR-SB, change | —Not reported | —Trial running · NCT06159673 |
| ADAS-Cog11, change | —Not reported | —Trial running · NCT06159673 |
| ADCS-ADL, change | —Not reported | —Trial running · NCT06159673 |
| MMSE, change | —Not reported | —Trial running · NCT06159673 |
| Amyloid PET, change (centiloids) | —Not reported | —Trial running · NCT06159673 |
CDR-SB, change
- LY03017
- —Not reported
- Remlifanserin
- —Trial running · NCT06159673
ADAS-Cog11, change
- LY03017
- —Not reported
- Remlifanserin
- —Trial running · NCT06159673
ADCS-ADL, change
- LY03017
- —Not reported
- Remlifanserin
- —Trial running · NCT06159673
MMSE, change
- LY03017
- —Not reported
- Remlifanserin
- —Trial running · NCT06159673
Amyloid PET, change (centiloids)
- LY03017
- —Not reported
- Remlifanserin
- —Trial running · NCT06159673
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
LY03017: no structured comparison results are available for Alzheimer's Disease.
Remlifanserin: no structured comparison results are available for Alzheimer's Disease.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LY03017's landscape · Remlifanserin's landscape